Vofatamab (FGFR3) - Research Grade Biosimilar
Product Specifications
Background
Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma) .
Immunogen
Humanized / FGFR3 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Cancer
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Fragment
IgG1-kappa
NCBI Organism
Homo sapiens
Other Product Names
MFGR1877S
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680633-100 1x 100 µL
Von Willebrand Factor (3E2D10), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040270-500 1x 500 µL
Fibronectin (HFN7.1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940669-100 1x 100 µL
P27 / KIP1 (SX53G8), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680679-100 1x 100 µL
CD171 / L1CAM (L1 Cell Adhesion Molecule) (UJ127), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400040-100 1x 100 µL
CD35 / CR1 (E11), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details